sheila RHEUMarampa
2 months ago
Key messages in the tx of ax/p-SpA:
>csDMARDs only effective in pSpA
>consider individualized treatment for bDMARDs and JAKis
>Cycling TNFi equally effective to switching
@RheumNow #EULAR2026 https://t.co/oeO3BxmYYo
Dr. John Cush RheumNow
2 months ago
JAK Safety Debate Continues: Stronger VTE signal, less clear cancer signal
Few topics in rheumatology have reshaped prescribing behaviour as dramatically as the safety concerns surrounding JAK inhibitors following ORAL Surveillance and the subsequent FDA and EMA warnings. https://t.co/mvTRRL7srA
Jiha Lee JihaRheum
2 months ago
Oral TYK2i deucravacitinib works for #PsA with OR without methotrexate. Pooled POETYK data (n=648): ACR20/50/MDA, enthesitis, dactylitis, skin responses, and PROs all comparable regardless of MTX use at wk 52. Good news for pts who can't tolerate MTX. @RheumNow #EULAR2026 POS0288
Janet Pope Janetbirdope
2 months ago
+#RCT in #dermatomyositis with #brepocitinib
Oral #TYK2/JAK1i
241 pts
+outcomes
#TIS total improvement score
>40%TIS 68% v 44%
#steroid tapering
#skin improved rapidly #CLASI
#OP0166
#POS0264 @RheumNow #EULAR2026 https://t.co/9WZl9RsXXe
Md Yuzaiful Md Yusof Yuz6Yusof
2 months ago
#EULAR2026 POS0713 Is there a hope for BTK-inhibition in #SLE despite several previous failures? A Phase IIb RCT in China: primary endpoint (SRI-4) was met in Orelabrutinib vs PBO in dose-dependent manner. No new safety signal. Phase 3 RCT is underway @RheumNow https://t.co/4cJ8ezppTS
Antoni Chan MD (Prof) synovialjoints
2 months ago
Gecacitinib (pan-JAK inhibitor) vs placebo in radiographic #axSpA ASAS40 51.9% vs 12.9% (p<0.0001) at 16 weeks. ASAS20 69.2% vs 21.2% (p<0.0001). Pan-JAK inhibition showed efficacy in TNFi-experienced patients. Abstr OP0240 @RheumNow #EULAR2026
Nelly ZIADE 🍀 Nellziade
2 months ago
Does sequential therapy infliximab —> tofacitinib outperform tofa alone in axSpA?
Yes: faster remission at week 4 (84.6% vs 15%)
But: equal at week 24
Prospective study in 46 patients
#POS0201 #EULAR2026 @RheumNow https://t.co/rmtoJQtYc0
sheila RHEUMarampa
2 months ago
Gecacitinib 100mg BiD vs PBO in active r-axSpA:
Met primary endpt ASAS40 at wk 16 showing efficacy of gecacitinib vs. PBO (51.9%vs12.9%,p<0.0001)
Gecacitinib showed ⬆️ improvements in ASDAS-CRP, physical fnxn, spinal mobility & QOL
Promising tx.
AbsOP0240 @RheumNow #EULAR2026 https://t.co/FytoRgxvnG
At EULAR 2026, two large phase 3 studies highlight that the JAK story in axSpA is still evolving rapidly, with different selectivity profiles and expanding global development programs continuing to push the field forward.
Dr. John Cush RheumNow
2 months ago
JAK Safety Debate Continues: Stronger VTE signal, less clear cancer signal
Few topics in rheumatology have reshaped prescribing behavior as dramatically as the safety concerns surrounding JAK inhibitors following ORAL Surveillance and the subsequent FDA and EMA warnings. Even https://t.co/wfQZn1hO3N
At the "What Is New in Psoriatic Arthritis" session at EULAR 2026, Professor Dennis McGonagle (Leeds, UK) took the audience on a whirlwind yet compact tour of the field, touching on three themes: the pathophysiology of PsA, individualization of clinical management, and emerging research and future directions.
Antoni Chan MD (Prof) synovialjoints
2 months ago
Ivarmacitinib (selective JAK1 inhibitor) significantly improved ASAS40 vs placebo in nr-#axSpA(39.7% vs 24.8%; p=0.006) at 12 weeks, sustained to 24 weeks. Another oral option for non-radiographic disease. Abstr OP0237 @RheumNow #EULAR2026
